Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  American Journal of Respiratory and Critical Care Medicine

• Publication date

  2010-11-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1164/rccm.201001-0137OCPMID 20622033
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cystic Fibrosis

  2009cited by this paper
• CFTR Delivery to 25% of Surface Epithelial Cells Restores Normal Rates of Mucus Transport to Human Cystic Fibrosis Airway Epithelium

  2009cited by this paper
• Cystic fibrosis

  2009cited by this paper
• Assessment of the CFTR and ENaC association.

  2009cited by this paper
• Impact of different chloride and glucose solutions on nasal potential difference

  2009cited by this paper
• High treatment burden in adults with cystic fibrosis: challenges to disease self-management.

  2009cited by this paper
• Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.

  2008cited by this paper
• PTC124 induces CFTR full-length production and activity in children with nonsense-mutation-mediated CF

  2008cited by this paper
• The changing face of the exocrine pancreas in cystic fibrosis: pancreatic sufficiency, pancreatitis and genotype

  2008cited by this paper
• PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model

  2008cited by this paper
• The prevalence of cystic fibrosis in the European Union.

  2008cited by this paper
• PTC124 targets genetic disorders caused by nonsense mutations

  2007cited by this paper
• Pulmonary

  2007cited by this paper
• Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.

  2007cited by this paper
• A review of the methodological features of systematic reviews in maternal medicine

  2007cited by this paper
• Laboratory parameter profiles among patients with cystic fibrosis.

  2007cited by this paper
• Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single‐ and Multiple‐Dose Administration to Healthy Male and Female Adult Volunteers

  2007cited by this paper
• Liver disease in cystic fibrosis

  2007cited by this paper
• In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study

  2007cited by this paper
• A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.

  2006cited by this paper
• CFTR genotype as a predictor of prognosis in cystic fibrosis.

  2006cited by this paper
• Molecular mechanisms of β2-adrenergic receptor function, response, and regulation

  2006cited by this paper
• Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation.

  2006cited by this paper
• Treatment burden and health‐related quality of life of children with diabetes, cystic fibrosis and asthma

  2006cited by this paper
• Genotype-phenotype correlation for pulmonary function in cystic fibrosis

  2005cited by this paper
• Early Decline of Pancreatic Function in Cystic Fibrosis Patients with Class 1 or 2 CFTR Mutations

  2005cited by this paper
• Chloride transport in nasal ciliated cells of cystic fibrosis heterozygotes.

  2005cited by this paper
• High-resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests.

  2004cited by this paper
• Early intervention and prevention of lung disease in cystic fibrosis: a European consensus.

  2004cited by this paper
• Pulmonary exacerbations in cystic fibrosis

  2004cited by this paper
• Standardized procedure for measurement of nasal potential difference: An outcome measure in multicenter cystic fibrosis clinical trials

  2004cited by this paper
• Basic protocol for transepithelial nasal potential difference measurements.

  2004cited by this paper
• Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations.

  2003cited by this paper
• Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.

  2003cited by this paper
• Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate.

  2002cited by this paper
• Aminoglycoside suppression of a premature stop mutation in a Cftr–/– mouse carrying a human CFTR-G542X transgene

  2002cited by this paper
• Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis * *

  2002cited by this paper
• Detecting early structural lung damage in cystic fibrosis

  2002cited by this paper
• Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients

  2002cited by this paper
• Cystic fibrosis: A worldwide analysis of CFTR mutations—correlation with incidence data and application to screening

  2002cited by this paper
• Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis.

  2001cited by this paper
• Nasal potential difference measurements in patients with atypical cystic fibrosis.

  2001cited by this paper
• Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis *

  2001cited by this paper
• Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.

  1999cited by this paper
• Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial.

  1999cited by this paper
• Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line

  1997cited by this paper
• Three, four or more: the translational stop signal at length

  1996cited by this paper
• Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations

  1996cited by this paper
• In Vivo Nasal Potential Difference: Techniques and Protocols for Assessing Efficacy of Gene Transfer in Cystic Fibrosis

  1995cited by this paper
• Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

  1994cited by this paper
• Pulmonary function between 6 and 18 years of age

  1993cited by this paper
• Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis

  1992cited by this paper

• Detailed evaluation of sleep apnea using heart rate variability: a machine learning and statistical method using ECG data

  2025cites this paper
• Ataluren improves hematopoietic and pancreatic disorders in Shwachman-Diamond syndrome patients: a compassionate program case-series

  2025cites this paper
• Systematic and quantitative analysis of stop codon readthrough in Rett syndrome nonsense mutations

  2024cites this paper
• Limb Girdle Muscular Dystrophy Type 2B (LGMD2B): Diagnosis and Therapeutic Possibilities

  2024cites this paper
• Readthrough compounds for nonsense mutations: bridging the translational gap.

  2023cites this paper
• Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.

  2023cites this paper
• Ataluren improves myelopoiesis and neutrophil chemotaxis by restoring ribosome biogenesis and reducing p53 levels in Shwachman–Diamond syndrome cells

  2023cites this paper
• Genome-scale quantification and prediction of pathogenic stop codon readthrough by small molecules

  2023cites this paper
• Promoting translational readthrough to augment fibrillin-1 (FBN1) deposition in Marfan syndrome fibroblasts: A proof-of-concept study

  2022cites this paper
• Ivacaftor

  2022cites this paper
• Novel Translational Read-through–Inducing Drugs as a Therapeutic Option for Shwachman-Diamond Syndrome

  2022cites this paper
• Clinical and molecular aspects of congenital aniridia – A review of current concepts

  2022cites this paper
• Mammalian proteome expansion by stop codon readthrough

  2022cites this paper
• One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies

  2022cites this paper
• Ataluren—Promising Therapeutic Premature Termination Codon Readthrough Frontrunner

  2021cites this paper
• Cystic Fibrosis

  2021cites this paper
• Inhibitors of Eukaryotic Translational Machinery as Therapeutic Agents.

  2021cites this paper
• The future of cystic fibrosis care: a global perspective.

  2020cites this paper
• Screening Readthrough Compounds to Suppress Nonsense Mutations: Possible Application to β-Thalassemia

  2020cites this paper
• Deciphering the molecular mechanism of stop codon readthrough

  2020cites this paper
• New Therapeutic Approaches in Cystic Fibrosis.

  2020cites this paper
• Kistik Fibroziste Yeni Terapötik Yaklaşımlar New Therapeutic Approaches in Cystic Fibrosis

  2020cites this paper
• ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease

  2020cites this paper
• CFTR and Cystic Fibrosis: A Need for Personalized Medicine

  2020cites this paper
• STATE OF THE ART Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications

  2020cites this paper
• A Novel G542X CFTR Rat Model of Cystic Fibrosis Is Sensitive to Nonsense Mediated Decay

  2020cites this paper
• Targeting the Underlying Defect in CFTR with Small Molecule Compounds

  2020cites this paper
• CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine

  2020cites this paper
• Re-imagining cystic fibrosis care: next generation thinking

  2020cites this paper
• Mutation-specific therapies and drug repositioning in cystic fibrosis.

  2019cites this paper
• Circulating Truncated Alpha-1 Antitrypsin Glycoprotein in Patient Plasma Retains Anti-Inflammatory Capacity

  2019cites this paper
• Molecular Therapies for Inherited Retinal Diseases—Current Standing, Opportunities and Challenges

  2019cites this paper
• Advances in Chitin/Chitosan Characterization and Applications

  2019cites this paper
• Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine

  2019cites this paper
• Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosis

  2019cites this paper
• Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis

  2019cites this paper
• Molecular Therapies for Cystic Fibrosis

  2019cites this paper
• Deciphering the Nonsense Readthrough Mechanism of Action of Ataluren: An in Silico Compared Study.

  2019cites this paper
• Neue Therapiemodalitäten bei Mukoviszidose

  2019cites this paper
• Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.

  2019cites this paper
• Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.

  2019cites this paper
• Recent Advances in Pediatric Ophthalmology

  2019cites this paper
• Using a systems approach to identify the mechanism of action of correctors

  2018cites this paper
• Factors influencing readthrough therapy for frequent cystic fibrosis premature termination codons

  2018cites this paper
• Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons

  2018cites this paper
• Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure

  2018cites this paper
• A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL QUANTITATIVER SCHNELLTEST ZUR MESSUNG VON CFTR-FUNKTIONEN BEI EINEM PRIMÄREN INTESTINALEN KULTURMODELL DOSAGE QUANTITATIF RAPIDE POUR MESURER LE FONCTIONNEMENT DE CFTR DANS UN MODÈLE DE CULTURES INTESTINALES

  2018influential citation
• Repurposing therapies for the personalised treatment of cystic fibrosis

  2018cites this paper
• Potentiators and Correctors in Paediatric Cystic Fibrosis Patients: A Narrative Review

  2018cites this paper
• Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis

  2018cites this paper
• Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice.

  2018cites this paper
• Gentamicin induces LAMB3 nonsense mutation readthrough and restores functional laminin 332 in junctional epidermolysis bullosa

  2018cites this paper
• The No-Go and Nonsense-Mediated RNA Decay Pathways Are Regulated by Inflammatory Cytokines in Insulin-Producing Cells and Human Islets and Determine β-Cell Insulin Biosynthesis and Survival

  2018influential citation
• Emerging pharmacotherapies in cystic fibrosis

  2018cites this paper
• Advances in the Diagnosis and Management of Cystic Fibrosis in the Genomic Era.

  2018cites this paper
• Chitosan in Non-Viral Gene Delivery: Role of Structure, Characterization Methods, and Insights in Cancer and Rare Diseases Therapies

  2018cites this paper
• A G542X cystic fibrosis mouse model for examining nonsense mutation directed therapies

  2018cites this paper
• Molecular basis of cystic fibrosis: from bench to bedside.

  2018cites this paper
• Mechanism and evidence of nonsense suppression therapy for genetic eye disorders

  2017cites this paper
• The suppression of premature termination codons and the repair of splicing mutations in CFTR

  2017cites this paper
• Title : Mechanism and evidence of nonsense suppression therapy for genetic eye 1 disorders 2 3

  2017cites this paper
• Toward inclusive therapy with CFTR modulators: Progress and challenges

  2017cites this paper
• New treatments targeting the basic defects in cystic fibrosis.

  2017cites this paper
• Rescue of the MERTK phagocytic defect in a human iPSC disease model using translational read-through inducing drugs

  2017cites this paper
• Etude de la régulation du canal CFTR impliqué dans la mucoviscidose par un analogue de la GnRHet le Mg2

  2017cites this paper
• Analysis of DFNB1 locus in presbycusis

  2017cites this paper
• Optimized approach for the identification of highly efficient correctors of nonsense mutations in human diseases

  2017cites this paper
• Ataluren in cystic fibrosis: development, clinical studies and where are we now?

  2017cites this paper
• Analysis of Azithromycin Monohydrate as a Single or a Combinatorial Therapy in a Mouse Model of Severe Spinal Muscular Atrophy

  2017cites this paper
• Overarching Concepts and Mechanisms Affecting Phenotypes of Ocular Genetic Conditions

  2017cites this paper
• CFTR functional assays in drug development

  2017cites this paper
• Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF).

  2017cites this paper
• Efficacy of Postnatal In Vivo Nonsense Suppression Therapy in a Pax6 Mouse Model of Aniridia

  2017cites this paper
• The nucleoside analog clitocine is a potent and efficacious readthrough agent

  2017cites this paper
• An Introduction to Clinical Aspects of Cystic Fibrosis

  2017cites this paper
• CFTR Modulator Therapies in Cystic Fibrosis

  2017cites this paper
• New horizons for cystic fibrosis treatment

  2017cites this paper
• Cystic Fibrosis: An Overview of the Past, Present, and the Future

  2017cites this paper
• Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.

  2017cites this paper
• Cystic fibrosis treatment: targeting the basic defect

  2017cites this paper
• Using stem cells to model MERTK deficient retinis pigmentosa

  2017cites this paper
• Lumacaftor/ivacaftor combination for CF patients homozygous for Phe508del-CFTR

  2017cites this paper
• Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs)

  2016cites this paper
• Nouvelles thérapeutiques ciblant le canal chlorure dans la mucoviscidose

  2016cites this paper
• Cystic Fibrosis and Its Management Through Established and Emerging Therapies.

  2016cites this paper
• Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.

  2016cites this paper
• Mukoviszidose

  2016cites this paper
• New drug developments in the management of cystic fibrosis lung disease

  2016cites this paper
• Translating the genetics of cystic fibrosis to personalized medicine.

  2016cites this paper
• Current and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its Symptoms

  2016cites this paper
• La mucoviscidose en 2014 : actualités thérapeutiques

  2016cites this paper
• Strategies to Correct Nonsense Mutations

  2016cites this paper
• From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations

  2016cites this paper
• Cystic fibrosis: a model system for precision medicine

  2016cites this paper
• 47 – Cystic Fibrosis

  2016cites this paper
• Cystic fibrosis: a clinical view

  2016cites this paper
• Therapie der Mukoviszidose mit CFTR-Modulatoren Treatment of Cystic Fibrosis with CFTR Modulators

  2016cites this paper
• Therapie der Mukoviszidose mit CFTR-Modulatoren

  2016cites this paper
• Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids.

  2016cites this paper
• Aminoglycoside-stimulated readthrough of premature termination codons in selected genes involved in primary ciliary dyskinesia

  2016cites this paper